Company ProfilePremium

Everlight Chemical Industrial Corporation

Company Profile Analysis

Ticker: 1711.TW臺灣永光化學工業股份有限公司

ESOMAR 23 Corporate BadgeISO Certifications Badge
Everlight Chemical Industrial Corporation - Company showcase

Year Founded & Workforce

1972

1,800 Employees

Everlight Chemical Industrial Corporation logo

Everlight Chemical Industrial Corporation Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Everlight Chemical Industrial Corporation Overview

Everlight Chemical is a 54-year-old Taiwanese fine- and specialty-chemicals group that is partway through a transition from a dye maker into a supplier of electronic and semiconductor materials. It runs five business units: Color Chemicals (textile reactive and disperse dyes, digital-textile inks), Specialty Chemicals (Eversorb® UV absorbers and hindered-amine light stabilisers), Electronic Chemicals (photoresists, developers, CMP slurries, wet-process chemicals, PSPI), Toner (through subsidiary 全通科技), and Pharmaceutical Chemicals (prostaglandin and other APIs). Consolidated revenue fell from NT$9.20 billion in FY2021 to NT$7.57 billion in FY2025, and FY2025 was a loss year. In 2026, however, Electronic Chemicals has become the second-largest unit, driven by photoresist contract manufacturing for international (mainly Japanese) chemical majors and by localisation of advanced-packaging supply chains. The equity now trades as a semiconductor-materials story, at roughly 3x book value. The company is raising new equity to fund electronic-chemical capacity.


Company's own description

The company's corporate website and annual-report summary describe Everlight as a company founded in 1972 under the philosophy of "pursuing progress and innovation, promoting humanity, and enhancing human welfare," with the cultural core of "honest operation and caring management." It describes its own trajectory as moving step by step from a traditional dye company into a "high-tech chemical enterprise group" with five businesses: color chemicals, specialty chemicals, toner, electronic chemicals and pharmaceutical chemicals. The company states that it has more than 1,800 employees worldwide, about 20 operating sites and 6 production bases (5 in Taiwan, 1 in Suzhou, China), and a sales network covering more than 100 countries on five continents. It also states that it spends more than 4% of revenue on R&D each year, employs about 200 R&D staff, and holds more than 200 patents.

S&P Global's business description, as reproduced by StockAnalysis, says the company sells chemical products and related raw materials in China, Taiwan, Europe, Asia, the Americas and elsewhere, and reports Pigment Chemistry, Specialty Chemicals, Pharmaceuticals Chemistry, Electronic Chemicals and Toner segments. Its product scope includes dyes for textiles, leather, inkjet, metal and paper; textile functional chemicals; digital textile inkjet inks; solar-sensitised dyes; and light stabilisers for coatings, plastics and PU/TPU.

Independent characterisation

Business unitCustomer typeEnd markets
Color ChemicalsTextile dyeing and printing mills, digital-print houses, brand-mandated supply chainsApparel, home textiles, sportswear (management noted demand from sporting events), leather, paper
Specialty ChemicalsPlastics compounders, coatings formulators, agricultural film makers, cosmetics, contact-lens makersAutomotive coatings, construction plastics, agri-film, solar encapsulants, personal care, ophthalmic
Electronic ChemicalsDisplay panel makers, LED/Mini/Micro-LED makers, semiconductor fabs and OSATs, chemical majors (contract manufacturing)Displays, power semiconductors, advanced packaging, SiC substrates
TonerCompatible-cartridge makers and OEMsOffice printing
Pharmaceutical ChemicalsGeneric and branded drug makers in 40+ countriesOphthalmology (prostaglandins such as latanoprost), cardiovascular (e.g., felodipine), oncology, veterinary

Everlight is a mid-cap, family-controlled, multi-niche specialty chemicals company with a manufacturing-led business model. Its core competency is organic synthesis and purification know-how built in azo and reactive dye chemistry. Over three decades the company has applied that know-how to:

  1. UV-absorber and light-stabiliser molecules (Eversorb®), where it competes with BASF's Tinuvin range. It began development in 1989 and started production in 1996.

  2. Photoactive and electronic materials, built on technology transferred from ITRI beginning in 1995. The company built a dedicated electronic chemicals plant in 1997.

  3. Prostaglandin and other high-potency APIs, with development from 1992 and a GMP plant completed in 1998.

  4. Chemically prepared toner, entered through the 1997 acquisition of 全通科技.

Revenue model. The business is almost entirely product revenue: chemicals sold by the kilogram or tonne. There is a growing contract-manufacturing (toll/OEM) component, mainly photoresist and other electronic chemicals made for international chemical majors that management describes as mostly Japanese. Management also mentioned a US company seeking non-China capacity. The contract-manufacturing share of revenue is not disclosed separately. There is no meaningful subscription or licensing revenue, although the company has received ITRI technology licences (as licensee) for photoresist and PSPI.

Value-chain position. Everlight sits in the middle of the chemical value chain. It buys petrochemical intermediates (naphthalene, phenols and other aromatics), acids, alkalis, salts and solvents, and for toner it buys acrylic/polyester resins, magnetic iron oxide and carbon black. It sells formulated or high-purity molecules to industrial converters: textile dyehouses, plastics and coatings compounders, display and semiconductor fabs and packaging houses, printer-cartridge makers and generic drug makers.

Customer types and end markets.

FX exposure. At the August 2025 investor conference, management said about 80% of transactions are priced in US dollars. On their estimate, a 10% appreciation of the TWD reduces revenue by about 8%, and each 1% TWD appreciation lowers gross profit by about 0.3–0.4%.

Strategy

Stated strategy (themes from 2025–2026 investor conferences and annual reporting)

Management's stated strategy has five themes:

  1. Portfolio migration to Electronic Chemicals. Redeploy resources and capacity from Color Chemicals to Electronic Chemicals and niche high-value products. Lift Electronic Chemicals to 25–30% of revenue (target stated in August 2025); it reached "nearly one quarter" in 2026.

  2. Semiconductor localisation and contract manufacturing. Take on contract manufacturing from international chemical majors, mainly Japanese, especially back-end advanced-packaging photoresists. Customers have asked Everlight to invest in capacity for them. Engage with US majors that want non-China capacity to serve China.

  3. Own-brand advanced materials. Expand sales of own-brand photoresists (PSPI, low-temperature OC and BM) and target front-end semiconductor process chemicals, back-end packaging PSPI, and low-temperature display materials for flexible displays and FOPLP.

  4. Defend legacy businesses through mix and pricing.

    • Color: pass costs through precisely in what management now describes as a seller's market, control inventory, push environmentally advantaged products, grow high-margin products, and adjust pricing models to be more resilient to FX and raw materials. Grow own-brand products.

    • Specialty: differentiated competition and flexible pricing to protect margins; faster new-product development.

    • Toner: substitute lower-cost raw materials, expand regional markets, and complete "the last mile" of restructuring.

  5. Green chemistry, circular economy and ZDHC leadership as commercial differentiators in textile supply chains.

Initiatives in the last 24 months

InitiativeTimingDetailStatus
Advanced-packaging photoresist contract-manufacturing line2025–2026New line built at customers' request; nearly complete April 2026Ramping; contributing quarterly
PSPI (EverPI P07) qualificationSampling since 2025, accelerated after the 2026 Japanese supply shortageSupplying power-semiconductor customers; advanced-packaging qualification ongoing as second or third sourceNot yet adopted in volume for advanced packaging (as of Apr and Oct 2026)
Electronic-chemical capacity expansionAnnounced 2026New production lines plus a hazardous-goods cold-storage warehouse at TaoyuanFunded by the cash capital increase
50 million-share cash capital increaseApproved 13 Aug 2026; effective 1 Oct 202640 million to existing holders, 5 million to employees, 5 million public offeringPricing pending; payment period Nov 2026
Contact-lens anti-blue-light UVA2025–2026Patented reactive UVA; orders from a "world-class" contract manufacturerEarly commercial
Perovskite PV encapsulant2025–2026Working with Taiwanese partners; management cites recognition in NatureEarly stage; small volumes
Eversorb 990 for PE agri-filmsc.2024Weatherability upgradeCommercial
Smart manufacturing (Plant 2)2023 onwardYokogawa S.I.R.I. roadmapImplementation not quantified
GHG reductionTarget set 2023 report−25% by 2030, aligned with Taiwan's 2050 net-zero pathIn progress

Medium-term targets and guidance

Everlight does not publish numerical revenue or earnings guidance. Management's qualitative stance at the April 2026 conference was cautious on global end-demand for Q2 and H2 2026, apart from textile demand tied to sporting events. Management said part of the March–April 2026 rebound reflected precautionary pull-forward buying driven by fears of supply-chain disruption. It was positive on electronic chemicals and contract manufacturing. Sell-side expectations reported in Taiwanese press (mid-2026) were for "high double-digit" profit growth in 2026. That expectation is not attributable to a named broker. The historical "NT$10 billion revenue" aspiration from the 2022 anniversary has not been reiterated as a dated target.

Products & Services

The company does not publish price lists. Pricing is negotiated (spot or contract for dyes and UVA; pre-agreed contract pricing for contract manufacturing). Management said in April 2026 that it is renegotiating contract-manufacturing price mechanisms to better absorb FX and raw-material swings.

Color Chemicals

Product lineDescription and capabilitiesTarget customerLatest notable version / yearNotes
Everzol® reactive dyesReactive dyes for cellulosic (cotton) fibres; high-exhaustion, energy-saving gradesCotton dyehousesEverzol® CS series (earth tones for cotton) won an MOEA Taiwan Excellence Gold Award in the 2020sPlant 1 verified Everzol Black-B 133% under ISO 14051 MFCA
Disperse dyesDyes for polyester and blendsSynthetic-fibre dyehouses, sportswear chains—Demand linked to sports events (Apr 2026 call)
Digital textile inksReactive, acid and disperse inkjet inks for digital textile printing, incl. cotton and silkDigital print housesOngoingPositioned as the low-energy, low-water route
Leather, paper and metal dyesSpecialty colourantsTanneries, paper mills, anodisers—Smaller lines
Textile functional chemicals / auxiliariesProcess auxiliariesDyehouses—ZDHC MRSL-conformant
Solar-sensitised dyesDyes for dye-sensitised solar cellsPV developers—Produced at Plant 4

Specialty Chemicals

Product lineDescriptionTarget customerYear / versionNotes
Eversorb® UV absorbers (benzotriazole, triazine, benzophenone classes)UV protection for plastics, coatings, adhesives, PU/TPUCompounders, coatings formulatorsProduction since 1996Company says the range complies with international regulations
Eversorb® HALSRadical-scavenging light stabilisersSameOngoing—
Eversorb 990Stabiliser for polyethylene agricultural filmsAgri-film makersLaunched c.2024 (per 2024 annual-report summary on ROIC.ai)Weatherability
Reactive anti-blue-light UVAPatented reactive UV absorber blocking 400–460 nmContact-lens makers (a "world-class contract manufacturer" order disclosed)Commercial 2025–26>1,000x conventional UVA unit price
Perovskite solar encapsulantEncapsulation adhesive for perovskite PVPV developers, Taiwanese partnersEarly commercial stageManagement cites recognition in a Nature report
Anti-yellowing agentsFor PU and textilesPU/textile processors——

Electronic Chemicals

Product lineDescriptionTarget customerStatusNotes
Photoresists (display)Resists for TFT-LCD, touch panels, AMOLEDPanel makersMature; mix shifted to small-size and AMOLED—
Low-temperature OC and BM photoresistsOvercoat and black-matrix resists for low-temperature, flexible displays and FOPLPDisplay and panel-level packaging makersCommercial, own brand—
Mini/Micro-LED photoresistsResists for LED patterningLED makersGrowth driver 2024–25Company says it is displacing foreign suppliers
Advanced-packaging photoresists (contract)Back-end thick-film or chemically amplified resists made under contract for international chemical majorsJapanese chemical majors; US major in discussionNew line nearly complete (Apr 2026), ramping quarterlyKey 2026 growth driver
EverPI® P07 (positive PSPI)Photosensitive polyimide for redistribution and passivation layersPower-semiconductor customers (in production); advanced-packaging/foundry (sampling)Supplying power semis; advanced-packaging sampling, positioned as second or third sourceTechnology from an ITRI transfer about five years ago; early use in automotive
Negative PSPIUnder developmentPackaging housesDevelopment—
CMP / polishing slurriesIncl. SiC substrate polishing slurrySiC wafer makersAdopted by customers, notably in China—
Wet-process chemicalsSemiconductor front-end wet chemicalsFabsDrove H1 2024 growth per the President—
Developers, thermal/UV-curable functional inksProcess chemicalsDisplay and PCB makersOngoing—

Toner (全通科技)

Product lineDescriptionTarget customerNotes
Mono and colour tonerPositive- and negative-charge toners for laser printers and copiersCompatible-cartridge makers, OEMsCapacity about 4,000 t/yr in 2010 with a 2,000 t line added (Commercial Times, 2010); current capacity not disclosed
Toner cartridges, carriers, developersFinished consumablesSameUS customers looking for non-China sources (2026 commentary)

Pharmaceutical Chemicals

Product lineDescriptionTarget customerNotes
Prostaglandin APIs (e.g., latanoprost)Ophthalmic glaucoma APIsGeneric drug makersDeveloped since 1992; registered in US, Canada, EU, UK, Japan, China
Cardiovascular APIs (e.g., felodipine)—Generic drug makersDMF-type registrations at the Kuanyin II plant
Oncology APIs—Same—
Veterinary APIs—Animal-health makers—
CDMO servicesCustom synthesisPharma clients2024 growth attributed to CDMO and launches into EU, US, Japan and LatAm

Regulatory status: the Plant 2 API facility is on the Taiwan FDA PIC/S GMP list. The company reports certification or inspection by Taiwan FDA, US FDA, EU authorities and Japan's PMDA. The latest US FDA inspection identified in sources was October 2019, classified VAI and closed via EIR.

Financial Narrative

Source: consolidated IFRS financial statements as compiled by S&P Global Market Intelligence (via StockAnalysis.com), cross-checked against company investor-conference disclosures. TWD millions unless stated.

Margins

Revenue CAGR: FY2021–FY2025 (4 years) ≈ −4.8% p.a. (derived). FY2020–FY2025 (5 years, FY2020 revenue NT$7,769 million per ROIC.ai) ≈ −0.5% p.a. (derived).

Quarterly trajectory (FY2025–H1 2026)

Q4 2025 EPS is −0.03 per CMoney and −0.04 per Yahoo (rounding). Q2 2026 margins were not available in sources accessed. The table uses "—" because they are not disclosed here. H1 2026 consolidated net profit was NT$155 million with EPS NT$0.28 (Yahoo/MOPS headline).

Balance sheet

Goodwill: none separately reported. Intangibles are immaterial at under 1% of assets.

Latest balance sheet (30 June 2026): total assets NT$14,026 million; cash and short-term investments NT$1,421 million; total debt NT$3,184 million (short-term debt NT$2,257 million, long-term NT$700 million); net debt NT$1,763 million; total equity NT$9,171 million; book value per share NT$16.29. The NT$669 million rise in "comprehensive income and other" in H1 2026 is consistent with mark-to-market gains on long-term equity investments; long-term investments rose from NT$897 million to NT$1,449 million.

Cash flow

Dividends paid in a calendar year relate to the prior year's earnings: NT$0.30/share paid in 2021 (FY2020), 0.50 in 2022, 0.35 in 2023, 0.15 in 2024, 0.30 in 2025, and none in 2026. No buyback programme was identified; S&P records a small "buyback yield" of 0.14–0.19% in some years, which is immaterial.

Commentary on trends, inflections and drivers

Revenue. FY2021 was a post-COVID restocking peak, with revenue up 18.4% on textile and toner demand. The following three years show a structural de-rating of the legacy businesses. Color Chemicals lost about NT$1.44 billion of revenue between FY2021 and FY2025 (−34%), as Chinese dye producers expanded capacity and global apparel destocked in 2022–23. Electronic Chemicals is the only unit with a sustained positive trend, growing from NT$1.23 billion to NT$1.82 billion (+48%) over the same period. FY2025's 7.3% decline came from two external shocks that management named explicitly: US tariff policy, which froze textile and consumer-goods supply chains from Q2 2025, and the strong appreciation of the TWD, which hit a revenue base that is about 80% USD-priced. Monthly revenue fell 15–17% YoY in May and June 2025.

Margins. Gross margin has fallen by about 500 bp in four years, from 24.1% to 19.0%. The trough was Q3 2025 at 15.95%, when FX, under-absorption and price competition in dyes and UVA all hit together. Operating leverage is high. SG&A plus R&D runs at about NT$1.6 billion a year (G&A NT$1.26 billion and R&D NT$0.38 billion in FY2025, per Simply Wall St), so a 1-point change in gross margin moves operating income by about NT$75–80 million. That explains why operating income swung from +NT$175 million to −NT$196 million on a 7% revenue decline. Q1 2026 gross margin recovered to 21.5%, the best in four quarters, and Q2 2026 EPS of NT$0.19 was the best single quarter since at least 2022.

Earnings quality. Non-operating items matter. H1 2025 had an FX loss of NT$62 million against a NT$65 million gain a year earlier, a NT$127 million swing. In November 2025, non-operating income turned an operating loss into a pre-tax profit. In Q1 2026, pre-tax profit (NT$66 million) was more than double operating profit (NT$30 million).

Balance sheet. Leverage is moderate. Net debt has been stable at NT$1.5–1.8 billion, and debt/equity has stayed around 0.35x through the cycle. The structure is weighted to short-term bank borrowing, with about NT$1.85–2.26 billion of short-term loans rolled continuously; this is typical for Taiwanese mid-caps. Liquidity is adequate but the quick ratio is below 1.0x because the business is inventory-heavy: DIO of 185–210 days reflects the wide range of dye SKUs.

Cash flow. Cash generation has weakened sharply. Free cash flow fell from NT$700 million in FY2023 to NT$62 million in FY2025 as capex more than tripled from NT$233 million in FY2021 to NT$776 million in FY2025, while operating cash flow fell. Construction in progress rose to NT$1.02 billion at FY2025, the electronic-chemical expansion and photoresist line, from NT$0.13–0.14 billion in FY2021–22. This capex step-up, combined with the April 2026 statement that expansion would be funded from internal cash and bank loans with "no current plan" for a cash capital increase or CB, sets the context for the August 2026 reversal to a 50 million-share equity raise.

Returns. ROE has never exceeded 5.5% in the five-year window and has been below the cost of equity throughout. The 2026 equity re-rating to about 3x book value therefore depends on a step change in returns from the electronic-chemicals mix, not on the historical return profile.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Business Units

UnitContentsRepresentative products

Color Chemicals (色料化學品)

Textile dyes, digital textile inks, leather, paper and metal dyes, textile auxiliaries

Everzol® reactive dyes (incl. CS series earth tones for cotton), Everlight disperse dyes, digital textile inks for cotton and silk

Specialty Chemicals (特用化學品)

UV absorbers, hindered-amine light stabilisers, anti-yellowing agents, specialty UVA for optics

Eversorb® UVA/HALS range, incl. Eversorb 990 for PE agricultural films; reactive anti-blue-light UVA for contact lenses

Electronic Chemicals (電子化學品, incl. nano-materials)

Photoresists, developers, CMP/polishing slurries, wet-process chemicals, functional inks, PSPI, contract manufacturing

EverPI® P07 (positive PSPI), low-temperature OC (overcoat) and BM (black matrix) resists, SiC substrate slurry, Mini/Micro-LED resists

Toner (碳粉)

Mono and colour toner, cartridges, carriers, developers

Made by subsidiary 全通科技 (Hsinchu)

Pharmaceutical Chemicals (醫藥化學品)

APIs and CDMO

Prostaglandin APIs (e.g., latanoprost), cardiovascular (felodipine), oncology, veterinary APIs

Revenue by Segment

Segment (Revenue, TWD Mn)FY2021FY2022FY2023FY2024FY2025

Color Chemicals Revenue (TWD Mn)

4,1963,5143,1433,0122,756

Specialty Chemicals Revenue (TWD Mn)

2,3652,4272,0122,1011,814

Electronic Chemicals Revenue (TWD Mn)

1,2291,3141,3231,6961,821

Toner Revenue (TWD Mn)

1,1701,4041,1621,134974

Pharmaceutical Chemicals Revenue (TWD Mn)

241233220226204

Total Segment Revenue (TWD Mn)

9,2018,8977,8758,1687,569

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Segment Margins & Growth (%)

Segment (YoY growth %)FY2022FY2023FY2024FY2025

Color Chemicals YoY (%)

-16.3-10.6-4.2-8.5

Specialty Chemicals YoY (%)

2.6-17.14.4-13.7

Electronic Chemicals YoY (%)

6.90.728.27.4

Toner YoY (%)

20.0-17.2-2.4-14.1

Pharmaceutical Chemicals YoY (%)

-3.4-5.62.7-9.7

Revenue by Segment (%)

Segment (% of total)FY2021FY2022FY2023FY2024FY2025

Color Chemicals (%)

45.639.539.936.936.4

Specialty Chemicals (%)

25.727.325.525.724.0

Electronic Chemicals (%)

13.414.816.820.824.1

Toner (%)

12.715.814.813.912.9

Pharmaceutical Chemicals (%)

2.62.62.82.82.7

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Segment (H1 2025) Overview

Segment (H1 2025)Revenue (TWD Mn)YoYShare of revenueSegment profit (TWD Mn)Profit change YoY

Color Chemicals

1,539+3%39%78−103

Specialty Chemicals

975−13%25%44−101

Electronic Chemicals

874+13%22%49

Flat

Toner

———

Loss widening (Apr 2026 call)

—

“—” = not publicly disclosed.

Segment Revenue

SegmentJan–Aug 2026 revenue (TWD Mn)YoYAug 2026 revenue (TWD Mn)Aug YoY

Color Chemicals

1,961+2%251+22%

Specialty Chemicals

1,407+11%168+13%

Electronic Chemicals

1,591+36%271+86%

Toner

≈632 (derived residual; press figure of 74.34 appears to repeat the monthly number)

≈+1% (reported)

74.34+31%

Pharmaceutical

114−10%5.98−63%

Total

5,705+11.64%747+33.16%

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (TWD Mn)

9,2018,8927,8618,1687,569

Revenue growth (%)

18.43-3.36-11.593.90-7.34

Gross profit (TWD Mn)

2,2131,9951,6001,7871,436

Operating income (TWD Mn)

55338183175-196

Depreciation & amortisation (TWD Mn)

701673652666659

EBITDA, derived = EBIT + D&A (TWD Mn)

1,2541,054735841463

Pre-tax income (TWD Mn)

597484109286-173

Net income (TWD Mn, S&P)

47337486244-117

EPS basic (TWD)

0.860.680.160.44-0.21

EPS diluted (TWD)

0.860.680.160.44-0.21

Cash dividend per share declared from FY earnings (TWD)

0.500.350.150.300.00

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Gross margin (%)

24.0622.4420.3521.8818.97

Operating margin (%)

6.014.281.062.15-2.59

EBITDA margin, derived (%)

13.611.99.410.36.1

Pre-tax margin (%)

6.495.441.393.50-2.29

Net margin (%)

5.144.211.092.98-1.55

Income Statement and Margin Analysis (%) (Quarterly)

MetricQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026

Revenue (TWD Mn)

1,9411,9871,8061,8352,0452,132

Gross margin (%)

22.3219.6815.9517.6321.52—

Operating margin (%)

1.02-0.98-5.61-5.181.83—

EPS (TWD)

0.07-0.13-0.11-0.040.090.19

Balance Sheet and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (TWD Mn)

14,13613,13312,90113,24312,794

Cash & short-term investments (TWD Mn)

1,5401,2191,5071,3661,217

Short-term debt incl. current LTD (TWD Mn)

2,0561,6781,7411,7791,892

Long-term debt (TWD Mn)

1,0001,0881,006864821

Total debt incl. leases (TWD Mn)

3,3283,0353,0052,8852,949

Net debt (TWD Mn)

1,7881,8151,4981,5191,732

Total equity incl. minorities (TWD Mn)

9,1068,8078,6568,8098,436

Equity attributable to parent (TWD Mn)

8,8068,4558,3448,5368,177

Intangible assets (TWD Mn)

562539874

Inventory (TWD Mn)

3,5303,9713,3903,4233,125

Receivables (TWD Mn)

1,8891,5581,6631,8161,664

Working capital (TWD Mn)

3,6194,1353,8283,6893,080

Construction in progress (TWD Mn)

1431262964911,023

Book value per share (TWD)

16.0815.4415.2315.5814.93

Cash Flow

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (TWD Mn)

7578531,336980838

Capital expenditure (TWD Mn)

233363636678776

Free cash flow (TWD Mn)

52449070030262

Common dividends paid (TWD Mn)

16427419282164

Share buybacks (TWD Mn)

00000

Cash interest paid (TWD Mn)

517110210799

Change in working capital (TWD Mn)

-520-279520-27314

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2021FY2022FY2023FY2024FY2025

ROE (%)

5.514.381.092.90-1.58

ROA (%)

2.531.750.400.84-0.94

ROIC (%)

4.182.870.701.52-1.91

Current ratio (x)

2.062.492.342.201.99

Quick ratio (x)

1.001.001.111.030.93

Debt / equity (x)

0.370.350.350.330.35

Net debt / EBITDA (x, S&P)

1.471.792.151.894.06

Interest coverage, EBIT / cash interest (x, derived)

10.95.30.81.6-2.0

Asset turnover (x)

0.670.650.600.630.58

Inventory turnover (x)

2.081.841.701.871.87

DSO, year-end (days, derived)

7363757878

DIO, year-end (days, derived)

184210198196186

DPO, year-end (days, derived)

3023344136

Cash conversion cycle (days, derived)

227250239233228

Data Point Details

Data pointValueSource

Regions of sale

China, Taiwan, rest of Asia, Europe, Americas, other

S&P / Yahoo company description

Currency of transactions

About 80% USD-denominated

26 Aug 2025 investor conference

Suzhou plant share of production value

About 20–25% (serving China domestic color and specialty demand)

Third-party analysis (uc913.com, Oct 2026); not company-verified

Overseas subsidiaries

USA (1991), Hong Kong (1992), Singapore (1997), Turkey/Mersin (1989), Suzhou (2006)

Company history page

China-specific trend

Electronic Chemicals: SiC slurry and photoresist growth "notably in mainland China" (H1 2025). Group revenue hit by "decline in the Chinese market" in 2025 (财讯快报, mid-2026).

Press summaries of company conferences

Japan

Main source of contract-manufacturing partners (Japanese chemical majors)

Apr 2026 conference

United States

Tariff-driven demand freeze in 2025. US toner and chemical customers seeking non-China sources in 2026.

Apr 2026 conference

Share Price and Market Valuation

MetricFY2021FY2022FY2023FY2024FY2025

Year-end close price (TWD)

25.5217.7219.1020.6219.15

Year-end market cap (TWD Mn)

14,92610,13310,73611,50310,489

P/E at year-end (x)

31.5627.06125.0347.220

P/B at year-end (x)

1.641.151.241.311.24

EV/EBITDA at year-end (x)

14.0912.2818.4216.3329.58

EV/Sales at year-end (x)

1.861.401.641.611.67

Performance Details

Performance (to close of 6 Oct 2026, NT$48.60)Return (price only, derived)Basis

Year-to-date 2026

+154%

vs. 31 Dec 2025 close NT$19.15

≈3-year

+154%

vs. 31 Dec 2023 close NT$19.10 (proxy)

≈5-year

+90%

vs. 31 Dec 2021 close NT$25.52 (proxy)

1-year

Not precisely verified. The 52-week low of about NT$17.05 (cnyes) implies a roughly 185% gain from the low; StockAnalysis showed market cap +181% YoY in mid-2026.

Proxy

52-week range

About NT$17.05 – NT$64.30

cnyes

Valuation Multiples

MultipleEverlightBasis

Market cap

≈NT$26.6 bn

547.16 m shares × NT$48.60

Enterprise value

≈NT$28.6 bn

  • net debt NT$1.76 bn + minorities NT$0.26 bn (Jun 2026)

P/E (TTM)

≈374x

TTM EPS NT$0.13 (Q3'25 −0.11, Q4'25 −0.04, Q1'26 0.09, Q2'26 0.19)

P/B

≈2.98x

BVPS NT$16.29 (Jun 2026)

EV/Sales (TTM)

≈3.7x

TTM revenue ≈NT$7.82 bn (FY2025 − H1'25 + H1'26)

EV/EBITDA (TTM)

≈60x

TTM-Mar-2026 EBITDA ≈NT$478 m implied by S&P (EV NT$21.43 bn / 44.86x)

Per-Share Data and Returns & Leverage Ratios (%)

MetricFY2021FY2022FY2023FY2024FY2025

Cash dividend per share declared from FY earnings (TWD)

0.500.350.150.300.00

Payout ratio (%)

585194680

Analyst Conclusions

Management guidance

There is no quantitative guidance. The qualitative message (28 April 2026) is cautious on global end-demand for Q2 and H2 2026, apart from textile demand tied to sporting events. Management noted that part of the March–April rebound was pre-buying. It was constructive on contract-manufacturing volumes rising "quarter by quarter," on Electronic Chemicals reaching about a quarter of revenue, and on new high-value products (contact-lens UVA, perovskite encapsulant). Funding for the expansion has changed: from "internal funds and bank loans, no current SPO plan" in April 2026 to a 50 million-share SPO in August 2026.

Consensus growth expectations

No formal consensus exists. Reported institutional expectations point to high double-digit profit growth in 2026 from the loss base of FY2025. Year-to-date data are consistent with this: Jan–Aug 2026 revenue was +11.6% and H1 EPS NT$0.28 against −NT$0.06 in H1 2025.

Bull case

  1. Mix-driven margin expansion. Electronic Chemicals grew 36% YTD to August 2026 while legacy units are flat to up mid-single digits. Each additional NT$1 billion of electronic revenue, at margins above the group's 19–22% gross margin, flows through a largely fixed SG&A base of about NT$1.6 billion. That could lift operating margin back above the FY2021 level of 6%.

  2. Capacity-backed contract manufacturing. The dedicated advanced-packaging photoresist line was built at customer request, and SPO proceeds add further electronic lines. This makes revenue more visible than a speculative own-brand ramp.

  3. PSPI optionality. Qualifying as a second or third source for advanced-packaging PSPI would add a high-margin, sticky permanent material. The company states PSPI margins are above the segment average, and switching costs protect incumbents once qualified.

Bear case

  1. Valuation already discounts success. About 374x trailing P/E, about 3.0x P/B and about 60x EV/EBITDA, for a company whose five-year peak ROE was 5.5%.

  2. Qualification uncertainty and narrative risk. Management has repeatedly said PSPI for advanced packaging is still sampling. April 2026 press claims of adoption were not borne out, and the stock moved through limit-up and limit-down sessions on those headlines.

  3. The legacy base still dominates. Color, Specialty and Toner made up about 73% of FY2025 revenue and declined 8–14% that year. They are exposed to FX (about 80% USD), tariffs and Chinese competition. Free cash flow fell to NT$62 million and is now being supplemented by dilutive equity.

Catalysts and monitorables (next 12 months)

Catalyst / monitorableTimingWhat to watch
SPO pricing and completionOct–Nov 2026Issue price, discount, take-up, specific-person allocations
Monthly revenue (MOPS, by the 10th of each month)MonthlyElectronic Chemicals YoY; total YoY against tough comps from Mar 2026
Q3 2026 resultsMid-Nov 2026Gross margin above 21%? Operating vs. non-operating profit mix
PSPI qualification newsOngoingFormal adoption by an advanced-packaging customer (company confirmation, not press)
New photoresist and electronic lines start-up2026–2027Utilisation; contract pricing mechanism changes
FY2026 results and dividend decisionMar 2027 / AGM May 2027Resumption of dividends; FY2026 EPS
USD/TWDOngoingEach 1% move ≈ 0.3–0.4% of gross profit
US tariff policy and textile demandOngoingColor and Specialty order trends
Polytronics stake valueOngoingEffect on book value and comprehensive income

Analyst verdict

Everlight Chemical is a credible but early-stage transformation story. A family-controlled Taiwanese dye maker with sub-cost-of-capital returns is being re-priced as a semiconductor-materials supplier. The operating evidence of a turnaround is real. Revenue is growing again (+11.6% for Jan–Aug 2026), Electronic Chemicals has overtaken Specialty Chemicals as the second-largest unit, quarterly EPS has gone from −NT$0.13 (Q2 2025) to +NT$0.19 (Q2 2026), and gross margin has recovered from a 15.95% trough. The contract-manufacturing route, building capacity for Japanese majors seeking Taiwanese localisation, is a lower-risk way into advanced-packaging chemistry than a pure own-brand push, and it uses Everlight's real strengths: synthesis depth, flexible plants and long-standing ITRI-derived photoresist know-how.

The equity, however, has moved well ahead of the fundamentals. At NT$48.60 the stock trades at roughly 3x book and around 370x trailing earnings, while the company's best return on equity in five years was 5.5%. The PSPI catalyst that fuelled the April 2026 surge remains, in management's own description, in sampling for advanced packaging, with Japanese incumbents preferred. About three-quarters of revenue still comes from FX-sensitive, competitively pressured legacy businesses. Free cash flow has nearly disappeared under a capex step-up, and management reversed its April statement on equity funding within four months by launching a roughly 9% dilutive SPO.

Overall, Everlight is a high-variance turnaround. It deserves close monitoring, but at current levels the risk-reward depends on outcomes that are not yet visible in reported numbers: a confirmed advanced-packaging PSPI win, sustained 21%+ gross margins, and a return to positive free cash flow after the new capacity is commissioned. Investors with a long horizon may prefer to wait for SPO pricing, Q3 2026 margins and formal qualification news before taking a position. Shorter-horizon participants should expect continued narrative-driven volatility.


APPENDIX — SOURCES

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenureBackground

Chen Chien-hsin (陳建信)

Chairman (representing Yung De Investment)

Chairman since 2009

Eldest son of founder Chen Ting-chuan. Nine-year succession track: chairman's assistant, then vice chairman, then chairman (Global Views, 2017).

Chen Wei-wang (陳偉望)

President and Director

President since 1 Jan 2001 (registry)

Second son of the founder. PhD in Industrial Engineering, University of Michigan (1996). Joined as head of R&D, then Vice President, reaching President in about six years. ZDHC Foundation board member from 2017, the only non-brand representative. Public face of the company's circular-economy and green-chemistry agenda.

Weng Kuo-pin (翁國彬)

Head of Finance Division; Spokesperson (acts as CFO)

Spokesperson since at least 2021

Presents financials at investor conferences

Other registered managers (2024 registry)

杜逸忠, 陳清泰, 陳克倫, 葉順興, 李復興, 梁仁陽, 孫哲仁

——

“—” = not publicly disclosed.

Board of Directors

DirectorCategoryAffiliation (per MOPS election announcement)

Chen Chien-hsin (陳建信)

Corporate director rep. (Yung De Investment)

Chairman, Everlight Chemical

Chen Ting-chi (陳定吉)

Director

Co-founder; long-time director

Chen Wei-wang (陳偉望)

Director

President

Chen Chien-ming (陳建銘)

Director

Director and General Manager, 全通科技 (toner subsidiary)

Chen Ju-ai (陳如愛)

Director (new 2024)

Assistant VP, Suzhou Everlight; founder's daughter

Li Yung-lung (李永隆)

Director

Long-time director

Kan Wen-yuan (干文元)

Director

Chairman, China Chemical (中華化學)

Lin Chao-wen (林昭文)

Director (new 2024)

—

Yang Wei-wen (楊偉文)

Independent director

Associate Professor of Law, Kainan University

Chang Yuan-chen (張原禎)

Independent director

Senior VP, ITRI technology-transfer affiliate (創新工業技術移轉)

Lin Hsiu-yu (林秀玉)

Independent director (new 2024)

—

Major Shareholders

Holder categoryStakeDateSource

Directors and supervisors combined

16.50%

2 Oct 2026

HiStock (TDCC-based)

Foreign investors

5.79%

2 Oct 2026

HiStock

Large holders (>1,000 lots)

39.04%

2 Oct 2026

HiStock

Yung De Investment Co. (family holding company)

Board seat held via 6.745 million shares registered to the representative (registry); historically 63–85 million shares registered under the founder as Yung De representative

Registry snapshots

Registry

Chen Ting-chi (陳定吉)

11.80 million shares (registry)

Registry

—

Chen Wei-wang (陳偉望)

6.30 million shares

Registry

—

Chen Chien-ming (陳建銘)

3.89 million shares

Registry

—

Competitive Landscape

Competitors by Segment

SegmentNamed competitorsEverlight positioning

Color Chemicals

Zhejiang Longsheng Group (owner of DyStar), Zhejiang Runtu, Archroma (which acquired Huntsman Textile Effects in 2023), Kiri Industries (India), Atul Ltd (India), Colourtex (India)

Differentiation through ZDHC/bluesign compliance and digital inks. Disadvantaged on cost against Chinese integrated producers.

Specialty Chemicals (UVA/HALS)

BASF (Tinuvin®/Chimassorb®), Songwon Industrial (Korea), ADEKA (Japan), Rianlon (利安隆, China), Clariant

Niche specialisation (agri-film, optics, contact lenses).

Electronic Chemicals — photoresist / PSPI

Tokyo Ohka Kogyo (TOK), JSR, Shin-Etsu Chemical, Fujifilm Electronic Materials, DuPont, Merck/EMD Electronics; PSPI: Toray, Asahi Kasei, HD MicroSystems/Resonac, Fujifilm

Second- or third-source local supplier. Contract manufacturer for Japanese majors. Benefits from localisation. Small scale.

Electronic Chemicals — Taiwan peers (equity comparables)

Sanfu Chemical (三福化, 4755), Tex Year (德淵, 4720), China Chemical (中華化, 1727), Chang Chun Group (private)

Same investor theme ("TSMC supply-chain materials")

Toner

—

Shrinking, price-competitive. US customers seeking non-China sources.

Pharmaceutical (prostaglandin APIs)

Yonsung Fine Chemicals (Korea), Chirogate International (Taiwan), Cayman Chemical (US), Chinese generic API makers

Small niche; regulatory track record (FDA VAI 2019)

Competitor Detail

MetricEverlight (FY2025)

Revenue

NT$7.57 bn

Revenue growth

−7.3%

Gross margin

19.0%

Operating margin

−2.6%

R&D intensity

≈5.0%

Competitive Advantages & Vulnerabilities

AdvantagesVulnerabilities

Local (Taiwan) supply for semiconductor localisation

Customers prefer Japanese PSPI incumbents for permanent materials (management's own words)

Existing ITRI-derived photoresist IP and 30 years of production

Contract-manufacturing pricing pre-agreed; Everlight absorbs cost swings

Diversified chemistries cushion single-market shocks

Legacy segments (color, specialty, toner) shrank 8–14% in FY2025

ZDHC/bluesign leadership with brands

Dye overcapacity in China compresses prices

Low leverage (D/E 0.35x)

About 80% USD revenue against a TWD cost base

Recent Developments

--

Company Snapshot

$243.4M

Revenue

1,800

Employees

1972

Founded

Taipei City, Taiwan

Headquarters

SWOT Analysis

Strengths

  • A growing electronic-chemicals franchise. Segment revenue rose from NT$1,229 million (FY2021) to NT$1,821 million (FY2025) and then +36% YoY in Jan–Aug 2026, making it the #2 unit (S&P; company monthly disclosures).
  • Contract-manufacturing relationships with international majors. Customers asked Everlight to invest in a dedicated advanced-packaging photoresist line, nearly complete in April 2026 (investor conference).
  • A moderate balance sheet. Debt/equity of 0.35x and net debt/equity of 0.21x at FY2025; current ratio 1.99x (S&P).
  • IP in niche molecules. Patented reactive anti-blue-light UVA sells at more than 1,000x the unit price of conventional UVA; positive-PSPI materials patent (April 2026 conference).
  • Regulatory credentials. API plant on the PIC/S GMP list; US FDA VAI with EIR (2019 inspection); registrations in the US, EU, UK, Japan, Canada and China (company and pharma directories).
  • Sustainability leadership in textiles. First chemical-company member of ZDHC (2015); President on the ZDHC board (2017); Plant 2 green-factory label (2023).

Weaknesses

  • Structural decline in the core color business. Revenue fell from NT$4,196 million to NT$2,756 million between FY2021 and FY2025 (−34%).
  • Weak returns. ROE peaked at 5.5% (FY2021) and was −1.6% in FY2025; ROIC was −1.9% in FY2025.
  • High FX sensitivity. About 80% of revenue is USD-priced; H1 2025 FX loss was NT$62 million against a NT$65 million gain in H1 2024.
  • Inventory-heavy working capital. DIO of about 186–210 days and a cash conversion cycle of about 228–250 days (derived).
  • Collapsing free cash flow. NT$700 million (FY2023) to NT$62 million (FY2025) as capex reached NT$776 million.
  • Toner losses. Revenue −14% in FY2025 and −11% in Q1 2026 with widening losses (April 2026 conference).

Opportunities

  • Advanced-packaging capacity build-out. TSMC announced global 3nm expansion and CoWoS expansion on 16 April 2026; Everlight targets back-end photoresists and PSPI.
  • Japanese PSPI supply tightness. Created sampling opportunities as a second or third source (August 2025 and April 2026 conferences).
  • Supply-chain de-risking from China. US majors are seeking non-China capacity; US toner customers are asking about alternative sources (2026 commentary).
  • New high-value optics and energy materials. Contact-lens UVA with an international order; perovskite encapsulant in partnership with Taiwanese firms.
  • Equity raise. About 50 million new shares fund capacity, allowing faster scale-up of electronic lines (August–October 2026 MOPS filings).
  • Polytronics stake revaluation. Long-term investments rose from NT$897 million (FY2025) to NT$1,449 million (June 2026), supporting book value.

Threats

  • PSPI qualification risk. As of 6 October 2026, the company says advanced-packaging PSPI is still in sampling, which conflicts with April 2026 press claims of adoption.
  • Valuation risk. At NT$48.60, trailing P/E is about 370x (derived from TTM EPS of NT$0.13) and P/B about 3.0x, against a 1.1–1.6x historical range.
  • Tariff and macro shocks. May–June 2025 monthly revenue fell 15–17% YoY on US tariff uncertainty.
  • TWD appreciation. Each 1% appreciation lowers gross profit by about 0.3–0.4% (management sensitivity).
  • Contract-pricing squeeze. Contract-manufacturing prices are agreed in advance, so Everlight absorbs input-cost changes (April 2026 conference).
  • Chinese competition in dyes, UVA (e.g., Rianlon) and toner, eroding legacy margins; FY2025 gross margin was 19.0%, the five-year low.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Apr 2025April revenue NT$732 m (+3.9% YoY); the last month of YoY growth before the tariff shockPre-shock baseline
May 2025May revenue NT$657 m (−16.8% YoY)Onset of tariff and TWD impact
29 May 2025AGM heldRoutine
30 May 2025Q1 2025 results: revenue NT$1.94 bn, EPS NT$0.07Last profitable quarter until Q1 2026
19 Jun 2025Ex-dividend NT$0.30 (FY2024 earnings)Last dividend paid to date
Jun 2025June revenue NT$598 m (−15.5% YoY)Demand trough
15 Aug 2025Q2 2025 results: EPS −NT$0.13Swing to loss
26 Aug 2025H1 2025 investor conference: revenue NT$3.93 bn (−4%), net loss NT$45 m, FX loss NT$62 m; Electronic +13%; target to lift Electronic to 25–30% of revenue in 2026Strategic framing of the pivot
Aug 2025Management cites Japanese PSPI shortage and local substitution interestSeeds of the 2026 PSPI narrative
13 Nov 2025Q3 2025 results: revenue NT$1.81 bn, EPS −NT$0.11; gross margin trough 15.95%Bottom of the cycle
Dec 2025November revenue NT$590 m (−11.2%); operating loss but pre-tax profit NT$5.95 m on non-operating income; Pharma +69% for the monthSigns of stabilisation
Jan 2026December 2025 revenue NT$660 m (−8.9%); FY2025 revenue NT$7,569 m (−7.34%)Full-year confirmation
Feb 2026January 2026 pre-tax profit NT$17.24 m, the first profitable month in the new yearInflection
Mar 2026February revenue NT$484 m (−33% YoY; Lunar New Year); operating loss NT$19.7 mSeasonal noise
Mar 2026Reports of a Japanese PSPI supply cut (press names Asahi Kasei); stock surges; TWSE "attention" disclosure (18 Mar 2026)Narrative catalyst
19 Mar 2026FY2025 results: operating loss NT$196 m, pre-tax loss NT$173 m, EPS −NT$0.21First annual loss in five years
Apr 2026March revenue NT$837 m (+28.2% YoY); Electronic +89%, Pharma +90%Strong rebound (partly pre-buying)
15 Apr 2026TAI-TECH buys 5.57% of Polytronics (Everlight is largest holder)Mark-to-market support for the affiliate stake
17 Apr 2026Limit-up to NT$47.95 on volume of about 70,000 lots after TSMC's 16 April call (3nm and CoWoS expansion); press claims PSPI "adopted"Valuation inflection. The claim of PSPI adoption by an advanced-packaging leader was later contradicted by the company.
20–23 Apr 2026Further limit-up sessions (press reports closes of NT$52.7 and NT$59.6 on the same day — conflicting sources); 52-week high NT$64.30, then limit-down to NT$50.9High volatility
28 Apr 2026FY2025/Q1 2026 investor conference: Q1 revenue NT$2.045 bn (+5%), operating profit NT$30 m (+26%), pre-tax NT$66 m; Electronic Q1 +44%, now #2 unit; PSPI for advanced packaging still sampling; new photoresist line nearly complete; "no current plan" for SPO or CBManagement tempers PSPI expectations
14 May 2026Q1 2026 accounts approved (EPS NT$0.09); staff appointed to the Polytronics board; manager appointed to Turkey Elite boardGovernance actions
28 May 2026AGM: FY2025 accounts approved; no profit distributionDividend streak broken
Jun 2026Press: Jan–May pre-tax profit NT$147 m; May operating profit NT$46.95 m; analysts expect high double-digit 2026 profit growthProfit recovery
7 Jul 2026June revenue NT$691 m (+15.5%); H1 revenue NT$4.18 bn (+6.34%); Electronic H1 +27%Recovery broadens
Aug 2026July revenue NT$781 m (+25.7% YoY)Acceleration
13 Aug 2026Q2 2026 accounts approved: EPS NT$0.19 (best quarter in years); H1 net profit NT$155 m, EPS NT$0.28. Board approves cash capital increase of up to 50 million shares.Earnings recovery plus dilution
8 Sep 2026August revenue NT$747 m (+33.2%); Electronic NT$271 m (+86%); Jan–Aug revenue NT$5.71 bn (+11.6%)Electronic momentum
30 Sep 2026Close NT$40.90; P/E (TTM) about 311x per forum dataElevated valuation
1 Oct 2026FSC declares cash capital increase effectiveRegulatory clearance
2 Oct 2026Record date 26 Oct; payment period 2–13 Nov (shareholders and employees), 16–27 Nov (specific persons); proceeds for electronic-chemical lines and hazardous-goods cold storageTimetable set
6 Oct 2026Stock limit-up to NT$48.60 amid a specialty-chemicals sector rally; company says PSPI mainly supplies power-semiconductor customers and is still sampling with advanced-packaging customersCurrent state

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

2 charts
Revenue by Segment: Total Segment Revenue fell from TWD 9,201 Mn in FY2021 to TWD 7,569 Mn in FY2025.
Everlight Chemical Industrial Corporation — Revenue by Segment
Series (TWD Mn)FY2021FY2022FY2023FY2024FY2025
Total Segment Revenue9,2018,8977,8758,1687,569
Color Chemicals Revenue4,1963,5143,1433,0122,756
Specialty Chemicals Revenue2,3652,4272,0122,1011,814
Electronic Chemicals Revenue1,2291,3141,3231,6961,821
Toner Revenue1,1701,4041,1621,134974
Pharmaceutical Chemicals Revenue241233220226204

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.